CMMB
NASDAQChemomab Therapeutics Ltd.
News · 26 weeks23-33%
2026-03-012026-08-23
Mix890d
- SEC Filings3(38%)
- Insider2(25%)
- Other2(25%)
- Earnings1(13%)
Latest news
25 items- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- PRChemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateProposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with substantial unmet need—nebokitug could potentially be the first novel mechanism RA therapy approved in the U.S. since 2012 Scipher’s AI Network Medicine platform identified first-in-class CCL24-blocker nebokitug as the highest ranked clinical-stage candidate for RA, potentially providing additional therapeutic benefit to the two-thirds of RA patients who do not achieve low disease activity or remission with current therapies Nebokitug RA Phase 2 clinical trial expected to begin in
- SECSEC Form SCHEDULE 13D filed by Chemomab Therapeutics Ltd.SCHEDULE 13D - Chemomab Therapeutics Ltd. (0001534248) (Subject)
- PRChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisCombined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support the selection of RA patients who potentially could benefit from treatment with nebokitug Phase 2 RA clinical study expected to read out in H1 2028, providing a potential key inflection point Combine
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- INSIDERSEC Form 3 filed by new insider Melincoff Gwen A3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- INSIDERChief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- PRChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update. "In the first q
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- INSIDERSEC Form 3 filed by new insider Mor George Adi3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Darvish Nissim3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen Neil Harris3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Moses Alan Charles3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fatal Sigal3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawler John3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quigley Jill M.3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nicaise Claude3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 20-F filed by Chemomab Therapeutics Ltd.20-F - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Chemomab Therapeutics Ltd.SCHEDULE 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)
- PRChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceTEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days. Oppenheimer 36th Annual Healthcare Life Sciences Confere
CMMB FAQ
7 questionsWhat does Chemomab Therapeutics Ltd. do?
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.Where does CMMB stock trade?
Chemomab Therapeutics Ltd. (CMMB) is listed on NASDAQ.What sector and industry is CMMB in?
Chemomab Therapeutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Chemomab Therapeutics Ltd. go public?
Chemomab Therapeutics Ltd. (CMMB) completed its IPO in 2019.What are analysts saying about CMMB?
Chemomab Therapeutics Ltd. has had 5 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $400.00 price target on 2024-05-13.What companies are similar to CMMB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CMMB side-by-side with any of them on Quantisnow.How can I track CMMB on Quantisnow?
Quantisnow aggregates Chemomab Therapeutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMMB to receive live email and push alerts on every new disclosure.